Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ropinirole
Drug ID BADD_D01966
Description Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547]. It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole [A35711].
Indications and Usage For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome.
Marketing Status Prescription; Discontinued
ATC Code N04BC04
DrugBank ID DB00268
KEGG ID D08489
MeSH ID C046649
PubChem ID 5095
TTD Drug ID D0R9EQ
NDC Product Code 43353-267; 55111-727; 43353-265; 0228-3660; 46708-262; 60429-822; 10135-677; 0228-3659; 68462-259; 0378-5505; 10135-676; 16729-238; 43353-258; 50090-4684; 55111-662; 50090-5167; 71335-1188; 71335-0064; 60429-818; 50090-4803; 10135-673; 68462-258; 43353-266; 68462-254; 46708-265; 71335-1231; 62332-109; 68462-257; 0228-3640; 0378-5502; 46708-264; 58032-1011; 0781-5786; 60429-821; 0378-5504; 16729-237; 10135-678; 70518-2439; 10135-679; 55111-659; 50090-2068; 71335-1982; 16729-233; 46708-266; 72189-222; 16729-232; 0378-5501; 0378-5503; 68462-253; 60429-817; 60429-823; 68462-255; 16729-235; 62332-108; 55111-661; 70518-2750; 60429-819; 55111-728; 0378-5525; 0781-5784; 0228-3658; 16729-234; 63629-8123; 10135-674; 10135-675; 68462-256; 61919-780; 0378-5550; 62332-110; 60429-820; 71335-1167; 62332-107; 0228-3661; 16729-236; 46708-263; 0781-5780; 0781-5788; 62332-111; 0781-5782
Synonyms ropinirole | 4-(2-(di-n-propylamino)ethyl)-2(3H)-indolone | ropinirol | SK&F 101468 | SKF 101468 | SK&F-101,468 | Requip | ropinirole hydrochloride
Chemical Information
Molecular Formula C16H24N2O
CAS Registry Number 91374-21-9
SMILES CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Genital candidiasis21.10.03.001; 11.03.03.002--Not Available
Gingival bleeding24.07.02.010; 07.09.07.001--Not Available
Gingivitis07.09.03.003; 11.01.04.013--
Glaucoma06.03.01.002--
Glossitis07.14.01.001--Not Available
Glycosuria20.02.01.005--
Goitre14.11.01.008; 05.02.01.001--Not Available
Gout15.01.06.001; 14.09.01.001--Not Available
Gravitational oedema08.01.07.005; 02.05.04.014--Not Available
Groin pain15.03.02.004--Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematoma24.07.01.001--
Haematuria24.07.01.047; 20.02.01.0060.000640%
Blood urine present13.13.02.002--Not Available
Haemoglobin13.01.05.018--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Haemoptysis24.07.01.006; 22.02.03.004; 02.01.02.006--Not Available
Haemorrhoids07.15.03.001; 24.10.02.002--
Hallucination19.10.02.0020.006830%
Hallucination, auditory19.10.02.0030.000854%Not Available
Hallucination, visual19.10.02.0040.004269%Not Available
Hallucinations, mixed19.10.02.0070.000427%Not Available
Head discomfort17.02.05.027--Not Available
Headache17.14.01.001--
Heart rate increased13.14.04.002--Not Available
Hemianopia17.17.01.012; 06.02.07.004--Not Available
Hemiparesis17.01.04.0010.000427%
Hemiplegia17.01.04.002--Not Available
Hepatic congestion09.01.05.008; 02.05.04.0130.000111%Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 25 Pages